Regeneron Pharmaceuticals (NASDAQ:REGN) EVP Joseph Larosa Sells 4,466 Shares of Company Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) EVP Joseph Larosa sold 4,466 shares of the company’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $965.49, for a total value of $4,311,878.34. Following the sale, the executive vice president directly owned 38,906 shares of the company’s stock, valued at approximately $37,563,353.94. This represents a 10.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Regeneron Pharmaceuticals Trading Down 4.4%

Shares of NASDAQ:REGN traded down $42.69 during midday trading on Wednesday, reaching $930.67. The company had a trading volume of 1,383,115 shares, compared to its average volume of 830,923. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.66 and a current ratio of 3.35. Regeneron Pharmaceuticals, Inc. has a 1-year low of $591.52 and a 1-year high of $991.73. The firm has a market cap of $95.82 billion, a price-to-earnings ratio of 20.55, a price-to-earnings-growth ratio of 1.51 and a beta of 0.10. The company has a fifty day simple moving average of $798.74 and a two-hundred day simple moving average of $740.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $16.51 by $3.56. The firm had revenue of $5.12 billion for the quarter, compared to the consensus estimate of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The business’s revenue for the quarter was up 36.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $11.83 EPS. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 49.10 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Friday, November 20th will be given a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 8.30%.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Zacks says improving earnings estimates could help support further near-term gains in REGN shares, following the stock’s recent advance. Why Regeneron Might Be Well Poised for a Surge
• Positive Sentiment: Analysts have raised price targets and several firms have expressed confidence in further appreciation. This follows Regeneron’s strong third-quarter results: revenue rose 36.3% year over year to $5.12 billion and EPS of $20.07 beat consensus of $16.51. Coverage also cited commercial performance and pipeline progress. RBC raises its price target Cantor Fitzgerald outlook Q3 results and pipeline coverage
• Neutral Sentiment: Director Kathryn Guarini sold 400 shares for $360,000 under a pre-arranged Rule 10b5-1 plan. The planned sale is less informative as a signal about the company’s outlook. Director share sale
• Negative Sentiment: The recent rally may leave room for valuation-related caution: some analyst targets remain below the share price, even as other firms have lifted their forecasts. The articles do not identify a fresh company-specific setback behind Wednesday’s weakness.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth about $5,682,636,000. State Street Corp increased its holdings in shares of Regeneron Pharmaceuticals by 3.6% during the 2nd quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock valued at $3,014,621,000 after acquiring an additional 170,210 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of Regeneron Pharmaceuticals by 8.5% during the 2nd quarter. Bank of America Corp DE now owns 1,291,053 shares of the biopharmaceutical company’s stock valued at $805,023,000 after acquiring an additional 101,469 shares during the last quarter. Amundi raised its stake in shares of Regeneron Pharmaceuticals by 0.4% in the 2nd quarter. Amundi now owns 1,013,540 shares of the biopharmaceutical company’s stock valued at $631,983,000 after acquiring an additional 3,742 shares in the last quarter. Finally, Legal & General Group Plc bought a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $473,872,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on REGN. Canaccord Genuity Group upped their price target on shares of Regeneron Pharmaceuticals from $875.00 to $922.00 and gave the stock a “buy” rating in a research note on Wednesday, October 28th. HSBC boosted their target price on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Zacks Research raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 28th. Evercore raised their price target on Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Finally, Weiss Ratings upgraded Regeneron Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $898.97.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.